IDEAS home Printed from https://ideas.repec.org/a/epw/ejmed0/v7y2025i2id42101.html

Analysis of Epirubicin in Treating Non-muscle Invasive Bladder Tumors: Retrospective Descriptive Analysis, Monocentric Study

Author

Listed:
  • Moussaab Rachid

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Ghassane El Omri

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Taghouan Anas

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Raiis Hamza

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Boularbah Karim

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Younes Houry

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

  • Abdeljalil Heddat

    (Department of Urology, Cheikh Khalifa International University Hospital, Mohammed VI University of Sciences and Health (UM6SS), Morocco)

Abstract

Purpose: BCG and MMC are the most popular drugs for adjuvant intravesical instillations in Non-Muscle-Invasive Bladder Cancer (NMIBC). In recent years, there has been a risk of shortage of these two agents worldwide. For this reason, our study aims to determine the characteristics of NMIBC in our department and the results following their treatment with Epirubicin. Methods: This inquiry is a retrospective descriptive study of 09 patients regrouped from the Urology Department of Cheikh Khalifa Hospital. Results: The results obtained revealed a predominance of low-grade urothelial carcinomas with an intermediate risk of recurrence and progression. Intravesical instillations of Epirubicin have shown a recurrence rate of 44.44% and a progression rate of 33.33%, with local side effects observed in 5 patients. Conclusion: Despite the limited number of patients in our study, treatment with Epirubicin has demonstrated therapeutic efficacity, approaching that of BCG and MMC, with an acceptable toxic profile.

Suggested Citation

  • Moussaab Rachid & Ghassane El Omri & Taghouan Anas & Raiis Hamza & Boularbah Karim & Younes Houry & Abdeljalil Heddat, 2025. "Analysis of Epirubicin in Treating Non-muscle Invasive Bladder Tumors: Retrospective Descriptive Analysis, Monocentric Study," European Journal of Medical and Health Sciences, European Open Science, vol. 7(2), pages 19-22, March.
    • Handle: RePEc:epw:ejmed0:v:7:y:2025:i:2:id:42101
    DOI: 10.24018/ejmed.2025.7.2.2101
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/ejmed/article/view/42101
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/ejmed/article/download/42101/10654
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/ejmed.2025.7.2.2101?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:7:y:2025:i:2:id:42101. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.